Caplin Point Announces Strong FY26 Results, Boosts Dividend Amid 13.2% Revenue Growth
Caplin Point Laboratories Limited, a pharmaceutical company, announced its financial performance for the quarter and year ended March 31, 2026. The company reported robust growth across its key markets, highlighting substantial increases in revenue and profits for the fiscal year.The Board of Directors also approved an Interim Dividend of INR 4.00 (200%) per equity share of face value INR 2 for the financial year ended March 31, 2026. The Record Date for determining shareholder eligibility for the dividend has been fixed as May 30, 2026.
Financial Performance Snapshot
The financial results for the year ended March 31, 2026, reflect a healthy expansion across the group's operations. On a consolidated basis, the company recorded a total revenue of 2,302.73 Crore, representing a 13.2% year-over-year (YoY) increase.Key financial figures for the year ended March 31, 2026, compared to the previous year, are detailed below:
| Metric | Year Ended March 31, 2026 (Crores) | Year Ended March 31, 2025 (Crores) | YoY Growth |
|---|---|---|---|
| Total Revenue | 2,302.73 | 2,033.90 | 13.2% |
| Profit After Tax (PAT) | 649.73 | 541.10 | 20.1% |
| EBITDA | 876.39 | 743.36 | 17.9% |
| Cash from Operations | 523.23 | 432.37 | - |
On a standalone basis, the company posted total revenue of 933.70 Crore for the year ended March 31, 2026.
Furthermore, the company reported strong liquidity metrics, with Free Cash Reserves standing at ₹1,471 Crore and Total Liquid Assets at ₹2,726 Crore as of March 31, 2026.
Global Market Expansion and Operational Highlights
The company's growth is attributed to its dual focus on Emerging Markets (Latin America & Africa) and Regulated Markets, particularly the United States.Emerging Markets Focus:
Caplin's Latin America operations remain a significant growth engine. Key updates include:
- Mexico: The company has secured approvals for 25 products, with a pipeline of over 120 products planned for filing within the next 18 months. Caplin has also won 11 General and Oncology products for Tenders supply in Mexico over the next 24 months, valued at $4 million.
- Chile: Progress continues with over 135 product licenses held in Chile. The company has won 15 products for Tenders supplies in Chile over the next 24 months, with a total value of around $10 million.
- R&D Integration: The General Category API unit in Visakhapatnam received a manufacturing license and has completed validations for 4 APIs, with plans to validate 12 more before the end of the year. The facility in Thervoy is expected to complete validations by Q3 FY27, with the first DMF filings planned in FY28.
US and Regulated Markets:
The US presence remains a key driver for growth.
- Caplin Steriles USA Inc (CSU): The US-based entity completed its first full year of operations, generating around $11 million in revenue and achieving 26.2% in EBITDA. CSU plans to launch 15 more products in the current year.
- Product Pipeline: The development pipeline remains strong, with approximately 15 products expected to be filed in the US within FY27, primarily in Pre-Filled Syringes and Ophthalmic segments.
- Manufacturing Capacity: To meet growing demand, the company is expanding its IV Bag lines capacity to 3X its current size.
Strategic Investments and Future Outlook
Caplin Point is investing heavily in building future capabilities and enhancing its operational footprint. The company has allocated an enhanced Capital Expenditure (Capex) budget of approximately ₹1,000 + Crores for various investment projects.The strategic investments include:
- Oncology Facility: The facility near Chennai has successfully completed its first Regulatory inspection.
- New Formulations: The OSD Facility in Puducherry is ongoing, and the COL Injectable Facility in Gummidipoondi is slated for completion by Q4 FY27.
- API Development: The Oncology API facility at Thervoy SIPCOT, Chennai, is in the civil activity completion stage, slated for Q4 FY27.
Management highlighted that the company's unique end-to-end business model, coupled with its history of maintaining a robust balance sheet and remaining debt-free, positions it strongly for future resilient and profitable expansion across diversified geographies and complex product segments.
CAPLIPOINT Stock Price Movement
Shares of Caplin Point Laboratories Limited are rallying to ₹1989 as of 2:13 PM, having surged 7.99% in live trading. The stock is showing intense market interest, trading on a substantial volume of 381,673 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.